Login to Your Account



Alnylam Signs Potential $1B RNAi Agreement with Takeda

By Tiffany Turner


Wednesday, May 28, 2008
Alnylam Pharmaceuticals Inc. took another step in advancing its RNAi portfolio Tuesday, inking a potential $1 billion deal with Tokyo-based Takeda Pharmaceutical Co. Ltd. that will give Cambridge, Mass.-based Alnylam a 50-50 share in the Japanese partner's development and commercialization efforts in RNAi therapeutics in the U.S. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription